Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Calcium transport in male reproduction is possibly influenced by vitamin D and CaSR

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Accelerated loss of oogonia and impaired folliculogenesis in females with Turner syndrome start during early fetal development

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Thyroid function in COVID-19 and the association with cytokine levels and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Cohort profile: The COPENHAGEN Minipuberty Study-A longitudinal prospective cohort of healthy full-term infants and their parents

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • D B Allen
  • P Backeljauw
  • M Bidlingmaier
  • B M K Biller
  • M Boguszewski
  • P Burman
  • Graham Butler
  • K Chihara
  • J Christiansen
  • S Cianfarani
  • P Clayton
  • D Clemmons
  • P Cohen
  • F Darendeliler
  • C Deal
  • D Dunger
  • E M Erfurth
  • J S Fuqua
  • A Grimberg
  • M Haymond
  • C Higham
  • K Ho
  • A R Hoffman
  • A Hokken-Koelega
  • G Johannsson
  • A Juul
  • J Kopchick
  • P Lee
  • M Pollak
  • S Radovick
  • L Robison
  • R Rosenfeld
  • R J Ross
  • L Savendahl
  • P Saenger
  • H Toft Sorensen
  • K Stochholm
  • C Strasburger
  • A Swerdlow
  • M Thorner
Vis graf over relationer

Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

OriginalsprogEngelsk
TidsskriftEuropean journal of endocrinology / European Federation of Endocrine Societies
Vol/bind174
Udgave nummer2
Sider (fra-til)P1-9
ISSN0804-4643
DOI
StatusUdgivet - feb. 2015

ID: 45922167